Encapsulation of Risperidone into Chitosan-based Nanocarrier via Ionic Binding Interaction  by Mudhakir, Diky et al.
 Procedia Chemistry  13 ( 2014 )  92 – 100 
1876-6196 © 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Peer-review under responsibility of the School of Pharmacy, Bandung Institute of Technology
doi: 10.1016/j.proche.2014.12.011 
ScienceDirect
International Seminar on Natural Product Medicines, ISNPM 2012 
Encapsulation of risperidone into chitosan-based nanocarrier via 
ionic binding interaction 
Diky Mudhakira*, Caroline Wibisonoa, Heni Rachmawatia  
School of Pharmacy, Institut Teknologi Bandung, Jl Ganesha 10, Bandung 40132, Indonesia 
Abstract 
Pharmaceutically active compounds risperidone has difficulty to be packaged into nanocarrier due to its positive charge. In this 
study, we encapsulated risperidone into chitosan-based nanocarrier via ionic interaction. The nanocarrier was consisted of 
chitosan:sodium TPP = 5.72:1 and prepared by ionic gelation method. Encapsulation efficiency was enhanced by modification of 
pH of chitosan, sodium tripolyphosphate (TPP), and the concentration as well as the surface charge of risperidone. The later was 
done by addition of SDS (Sodium Dodecyl Sulphate) minimum 0.005% (w/v). The particle size was in the range of 300-400 nm. 
Encapsulation efficiency of risperidone was reached up to 25.62% with addition of 0.050% SDS. Encapsulation of risperidone 
into chitosan-TPP nanocarrier was increased by modification of risperidone’s charge with low concentration of SDS. Further 
amount of SDS higher than 0.1% increased the particle size to microparticles. Chitosan-based type nanocarrier was preferable for 
encapsulating anionic drugs via ionic interaction. 
© 2014 The Authors. Published by Elsevier B.V. 
Peer-review under responsibility of the School of Pharmacy, Bandung Institute of Technology. 
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1. Introduction 
Risperidone is a positively charged antipsychotic drug used for treatment of schizophrenia and other psychoses 
and in short term treatment of mania associated with bipolar disorder. Nowadays, risperidone is commercially 
delivered in tablet and injection dosage form. Risperidone in oral administration will significantly metabolized into 
its active metabolite with longer halflife in blood circulation, but lower capacity of blood brain barrier penetration so 
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the efficacy would be reduced as well. One approach to this problem would be control the release of risperidone and 
avoid the formation of its metabolite. Risperidone is claimed to produce a relatively low incidence of extrapyramidal 
effects than conventional antipsychotic agents. However, the risk of it with risperidone appears to be dose 
dependent. A low-dose risperidone therapy is required to control the psychotic symptoms, and long-term treatment 
is needed to treat schizophrenia. The use of this drug in the lowest possible effective dosage is recommended for 
minimizing the risk of the major adverse effects. Extended release formulation of nanoparticle risperidone via 
parenteral route will reduce the frequency of administration, as well as dose and dose-dependent EPS during the 
short-term management of psychotic disorders1. 
Polymeric nanoparticulate drug delivery system offers numerous advantages over the conventional dosage forms. 
These include improved efficacy, reduced toxicity, and improved patient compliance. This nanosized carrier possess 
quite good performance due to the high of specific surface area, in particular, nanoparticles are able to protect drug 
from degradation, to improve permeation/penetration of the drugs across mucosal surfaces, and also to control the 
release of the encapsulated or adsorbed drug2. Among those various polymers used for drug carrier, chitosan and its 
derivatives are the most used polymers. Chitosan is a natural cationic polysaccharide prepared by partial 
deacetylation of chitin, a copolymer which composed of glucosamine and N-acetyl glucosamine units. This cationic 
polymer is extensively used as carrier for drug delivery due to its biocompatibility and low toxicity. The most 
widely developed method for preparation of chitosan nanoparticles is an ionic gelation technique. This method 
offers many advantages such as simple and mild preparation method without the use of nontoxic and organic 
solvent, also easier to control. Principle of this method is based on ionic interaction between positively charged of 
primary amine group of chitosan and negatively charge polyanion group such as sodium tripolyphosphate, the most 
widely used crosslinking agent because of its nontoxic and multivalent characteristics. This physical cross-linking 
process not only avoids the use of chemical cross-linking agents and emulsifying agents which are often toxic to 
organisms, but also prevents the possibility of damage to drugs, particularly biological agents3. 
In this study, we used chitosan-sodium TPP as nanocarrier for encapsulating risperidone. However, since surface 
charge of chitosan and risperidone is the same; positive charge, encapsulation of the drug in chitosan based-
nanocarrier would be difficult. We conducted various technique and modification was to improve its encapsulation 
efficiency. 
2. Experiments 
2.1. Material 
Chitosan with various viscosity levels was obtained from Biotech Surindo and Crangon-crangon as a gift sample. 
Sodium Tripolyphosphate (TPP) was purchased from Sigma Aldrich (St. Louis, MO). Poloxamer 188 was obtained 
from PT. DankosFarma (Indonesia). The following materials was obtained from PT. Kalbe Farma Indonesia and 
used as received: risperidone, acetic acid glacial, sodium hydroxide, and absolute alcohol. 
2.2. Methods 
2.2.1. Chitosan-based nanoparticles preparation  
Chitosan-based nanoparticles were prepared using ionic gelation method. Chitosan was dissolved in 1% acetic 
acid to obtain chitosan solution of 3.15 mg/mL.  Adjustment of chitosan solution to pH 5 was done by addition of 
sodium hydroxide1N to maintain positive charge of chitosan. Sodium TPP was dissolved in aquademin to obtain the 
concentration of 1.65/mL. Chitosan solution was magnetically stirred at 880 rpm for 20 minutes at room 
temperature. Sodium TPP was slowly added using disposable syringe into chitosan solution until the translucent 
nanoparticles suspension was formed. In the preparation of chitosan-based nanoparticles, various concentration of 
SDS (0.001% up to 0.250%) were added to risperidone solution pH 3, 7, and 9 in order to modify its surface charge. 
Risperidone solution was added to SDS solution with continuously stirring for 10 minutes.   
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2.2.2. Encapsulation of risperidone into chitosan-based nanocarrier 
Specific concentration of risperidone was dissolved in 1% acetic acid to obtain pH 3 of risperidone solution. In 
order to obtain pH 9 solution, risperidone was added to absolute alcohol and water with ratio of 2:5 (v/v). While pH 
7 of risperidone solution was obtained by dissolving it to absolute alcohol and 1% acetic acid.Risperidone solution 
(pH 3, pH 7, and pH 9) was added into chitosan solution with continuously stirring at 880 rpm for 10 minutes. 
Sodium TPP solution was then added until the translucent nanosuspension was formed. Surface charge of 
risperidone was modified by addition of 0.003%; 0.005%; 0.010%; 0.050%; 0.100%; and 0.250% SDS into 
risperidone solution pH 9 before mixed with chitosan solution.  
2.2.3. Characterization and morphology of chitosan nanoparticles 
The mean particle size and polidispersity index of nanoparticle suspensions were measured using dynamic light 
scattering method (Delsa Nano® C Series, Beckman Coulter). Samples were directly measured without dilution. The 
zeta potential value was performed by laser Doppler effect using Delsa Nano® C Series, Beckman Coulter. 
Morphology of nanoparticle suspensions were examined using either using light microscope (Nikon® E50i Pol) or 
SEM (Scanning Electron Microscope) methods.  
2.2.4. Encapsulation Efficiency of Risperidone in Chitosan-based Nanocarrier 
Encapsulation efficiency of risperidone was calculated using Eq.1. Risperidonenanosuspensions was centrifuged 
at 1397.5 x g for 30 min, supernatants were then collected and measured spectrophotometrically at 275 nm for 
risperidone assay.  
             % EE :                                                                           (1) 
 
3. Results and Discussion 
3.1. Initial Formula 
In early stage of study, several formulas were designed to prepare chitosan-based nanocarrier, particularly the 
ratio of chitosan and sodium TPP (Table 1).  
Table 1.  Ratio chitosan:sodium TPP in nanoparticles preparation 
Physical 
appearance 
Chitosan 
1 2 2.86 3 4 5 5.72 10 
TP
P 
pH
 9
.6
 1 X X √ X X X √ √ 
2 - X - X X - - X 
3 X - - X - - - - 
   Note: √ = nanosuspension, X = macrosuspension/sedimentation 
Sodium TPP (10 mg/mL) was slowly added into acidic aqueous chitosan to obtain mixture with various ratios as 
shown in Table 1. As results, nanosuspesion was derived from the ratio of chitosan and sodium TPP of 2.86:1; 
5.72:1; and 10:1, respectively. Phenomenon occurred was macro suspension or sedimentation and translucent 
nanosuspension. Those were because of the difference of ionic strength between various ratio of chitosan and 
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sodium TPP. In acidic condition, there is not only electrostatic repulsion due to the protonated amino groups, but 
also interchain hydrogen bonding interactionsin chitosan molecules. It was reported that the intermolecular 
hydrogen bonding attraction and the intermolecular electrostatic repulsion were in equilibrium at concentration of 
chitosan less than 2.0 mg/mL3. Therefore, as the concentration increased until 2.0 mg/mL, they approached each 
other with a limit, leading to a limited increase in intermolecular cross-linking, thus larger but still nanoscale 
particles were formed. Above this concentration, microparticles were easily formed probably due to the stronger 
hydrogen bonding interactions leading to plenty of chitosan molecules involved in the cross-linking of a single 
particle. The formation of micro-particles usually lead to a flocculant precipitate due to the electrostatic repulsion 
between particles is not sufficient to maintain the stability of these large particles3. Formation of chitosan/TPP 
nanoparticles was mainly determined by specific ratio of both components. Table 2 shows the ratio and specific final 
concentration of chitosan and TPP to form stable nanoparticle suspension. The best density achieved was chitosan of 
2.1 mg/mL and sodium TPP of 0.367 mg/mL, with average diameter particle size of 697.40 nm. 
Table 2.  Characteristics of nanoparticles with various ratios and concentrations of chitosan/TPP 
Form Ratio  Chi : TPP 
Chitosan TPP 
(mg/mL) pH 
Particle 
Size (nm) PI pH 3 (mg/mL) pH 4 (mg/mL) 
F-35 5.72 : 1 2.1 - 0.367 3.67 697.40 0.162 
F-36 5.78 : 1 2.6 - 0.450 3.69 943.70 0.268 
F-38 5.78 : 1 - 2.6 0.450 4.16 1234.90  0.382 
3.2. Variation of chitosan: sodium TPP concentration  
The chitosan/TPP nanoparticles were prepared with different concentration of chitosan and sodium TPP. It was 
demonstrated that the increase concentration of chitosan and sodium TPP enhanced the particle size4. This fact was 
proved in this study, whenever lowering both concentration of chitosan and sodium TPP to 1.575 mg/mL and 0.275 
mg/mL, respectively decreased the particle size approximately 681.40 nm.  Further reduce both concentrations led to 
smaller particle size of 454.30 nm. It is presumably that a lower viscosity of gelation medium with lower chitosan 
concentration resulted in a decrease of the liquid phase resistance against dispersion, forming smaller nanoparticles5. 
Besides that, size decrease is attributed to the cross-linking effect, which induces the condensation of polymeric 
chains, resulting in smaller particles. The simultaneous decrease in zeta potential is a consequence, not only of the 
inclusion of a negatively charge material in the matrix of nanoparticles, but also of the general size decrease, which 
possibly exposes a lower number of charge groups because of the diminished surface6. 
Table 3.   Effects of chitosan/TPP concentration on the particle size 
Form. Chitosan (mg/mL) 
TPP 
(mg/mL) 
Particle Size 
(nm) PI 
F-35 2.100 0.367 697.40 0.162 
F-41 1.575 0.275 681.40 0.277 
F-43 1.050 0.183 454.30 0.287 
3.3. Variation of chitosan viscosity  
The characteristics of chitosan/TPP nanoparticles using different viscosity of chitosan were also investigated. As 
shown in Table 4, chitosan with viscosity of 20.5 and 46.6 cps did not appear to affect the particle size significantly, 
while 222 cps of chitosan did enhanced two-fold of particle size. These results consistent with the fact that the use of 
high viscosity chitosan resulted in larger nanoparticles7. 
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Table 4.   Effects of chitosan viscosity on the particle size 
Formula K of Chitosan (cps) Size (nm) PI 
F-48 222 634.2 0.289 
F-42 46.6 382.4 0.293 
F-50 20.5 352.8 0.282 
3.4. Variation of stirring rate 
We utilized some variations in stirring rate to form nanoparticles. It seemed that the stirring rate was concomitant 
with the particle size since the use of higher stirring rate decreased the particle size. Basically, stirring accelerates 
dispersion of TPP in chitosan solution and the increase shear force improves the monodispersity. However, intense 
stirring may destroy the repulsive force between particles and lead to formation of larger particles due to 
aggregation3.     
Table 5.   Effect of stirring speed on particle size 
Formula Stirring Rate (rpm) Size (nm) PI 
F-50 180 665.2 0.313 
F-50 335 614.5 0.247 
F-50 880 352.8 0.282 
3.5. Encapsulation of risperidone 
The formula used for preparing nanocarrier encapsulating risperidone was F-43 in which the concentration 
chitosan and sodium TPP were 1.050 mg/mL and 0.183 mg/mL, respectively. Various concentrations of risperidone 
were used to investigate nanoparticles characteristics and encapsulation efficiency. As results, the increase 
risperidone densities from 0.105 to 1.050 mg/mL formed nanoparticles with diameter in the range of 300-400 nm. 
However, all formula tested almost did not entrap risperidone in the system (data not shown). It is likely that 
chitosan and risperidone have positively charge so that it generated pulse reaction between the two molecules. 
Risperidone is a weak base compound with pKa of 8.24 and 3.11. In low pH, risperidone is in a dissolved state 
and has cationic charge, as in our study risperidone in pH 3 had positive charge +56.83 mV. Meanwhile chitosan is a 
weak polyelectrolyte with pKa around 6.5 and in acidic condition, the amine group of chitosan undergoes 
protonation to be cationic charge. The charge of chitosan pH 3 and pH 5 were +74.0 mV and 36.3 mV. This is in 
good agreement that more acidic chitosan increased the positively charge surface molecules. It means that in acidic 
condition, there was only weak hydrogen bonding between chitosan and risperidone instead of ionic interaction due 
to its positive charge. When sodium TPP which a polyanionic compound was added later, the bond was not quite 
strong against the specific interaction of chitosan and sodium TPP. Thus, protonated amine group of chitosan would 
bind to tripolyphosphate ion of sodium TPP and formed nanoparticles with no binding of risperidone. 
pH of chitosan has an important role either in crosslinked with sodium TPP and its interaction with risperidone. 
Its protonation level is mainly controlled by pH. It was reported that the pH of chitosan was concomitant with its 
protonation degree3. When pH of chitosan was increased from 4.7 to 8, protonation degree was decreased rapidly 
from 100 to 0%. It seemed that there was a critical pH in which chitosan started to be deprotonated. Additionally, 
the charge number and ionic species of TPP are affected by pH. In basic pH TPP of 9.7, concentration of 
tripolyphosphoric ions (P3O105−and HP3O104−) is high but the concentration of hydroxide ions is also present. The 
hydroxide ions or tripolyphosphoric ions in the medium can be competitively react ionically with the protonated 
amino groups of chitosan by deprotonation or ionic cross-linking. Moreover, the hydroxide ions are supposedto be 
preferentially bind to the protonated amino groups due to their higher mobility. Thus, it is inferred that as TPP 
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solution is mixed with chitosan solution, when the pH of chitosan solution is below the critical pH, the hydroxide 
ions in TPP solution are partially neutralized by the hydrogen ions in chitosan solution. The remaining hydroxide 
ions (if any) have little effect on the protonation degree of chitosan and the chitosan maintains its fully protonated 
state. Then the protonated amino groups are linked via tripolyphosphoric ions in spite of the strong intramolecular 
electrostatic repulsion. When the pH of chitosan is nearly the critical pH, the remaining hydroxide ions may have an 
apparent effect on the protonation degree of chitosan and the chitosan becomes less extended, which favors the 
formation of a particle structure. When the pH of chitosan is above the critical pH, the chitosan is already less 
protonated and the remaining hydroxide ions will cause a significant decrease in the protonation degree of chitosan 
and the potential capacity of chitosan to form cross-linking with tripolyphosphoric ions is supposed to decrease [3]. 
According to theory above, chitosan was adjusted to pH 4.7 – 5.0 to provide the optimum condition for ionic 
interaction with sodium TPP. Risperidone was then adjusted to pH 7 and pH 9 to modify its surface charge 
becoming negative so that it could be attached to the chitosan via ionic binding interaction. It was investigated that 
the increase of pH risperidone in almost lineary decreased the zeta potential value.      
3.6. Variation of pH risperidone 
Variation of pH of risperidone solutions (pH 3, pH 7, pH 9) were used to investigate surface charge of particles. 
Zeta potential value was determined at both before and after addition of sodium TPP in order to investigate whether 
there was chitosan-risperidone interaction (Fig. 1).  
 
 
 
 
 
 
 
 
Fig. 1.Effects of sodium TPP pH 9 on the charge of risperidone nanoparticles. 
As shown in Fig.1., the zeta potential of chitosan was decreased by adding risperidone (pH 3, pH 7, and pH 9). 
The most significant reduction occurred in chitosan pH 5 and risperidone pH 9. It is presumably that risperidone at 
pH 9 was less positively charge compared to others. Though, addition of sodium TPP leads to increase back the zeta 
potential value of all formula tested (chitosan pH 5 – risperidone pH 3, 7, 9). These results indicated that negatively 
charge TPP was more strongly interact with the chitosan through specific crosslinking reaction between amine 
group of chitosan with tripolyphosphate ion. Therefore, risperidone was not bound to chitosan. It was also proved in 
this study through the encapsulation efficiency which there was no risperidone entrapped in the chitosan/TPP 
nanocarrier system (data was not shown).   
3.7. pH variationof chitosan  
Varying pH of chitosan solution (pH 3 and pH 5) was also done to investigate the interaction between risperidone 
and sodium TPP by measuring zeta potential value. Risperidone was prepared at pH 9 as it was shown the most 
significant decrease in the zeta potential. The results indicated that chitosan pH 5 was better than pH 3 in decreasing 
the zeta potential value when it mixed with risperidone pH 9. However, the results of addition effect of sodium TPP 
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on the particle charge were the same as the study above that risperidone was not bound to chitosan (Fig. 2). The 
result of entrapment efficiency also indicated that there was no risperidone encapsulated in chitosan/TPP nanocarrier 
(data was not shown). 
 
 
 
 
 
 
 
Fig. 2.Effects of sodium TPP pH 9 on the charge of risperidone nanoparticleswith the use chitosan pH 3 and pH 5. 
3.8.   Variation of pH sodium TPP  
Crosslinking interaction between chitosan and TPP was investigated by varying pH of sodium TPP solution in 
pH 3 and pH 9. It was known that in its original pH of sodium TPP, it dissociates into hydroxide ion (OH-) and 
tripolyphosphate ion (H3PO104-dan P3O105-) while in lower pH, there is only ion P3O105. Chitosan is a weak base and 
lowering the pH enhances ionization of its amine group. Thus, chitosan/TPP particles formed at pH 9 would be 
dominated by deprotonation and few ionic crosslinking reaction. In contrast, particle formation would be more 
affected by ionic crosslinking8. Addition of sodium TPP pH 3 into chitosan-risperidone showed in decrease of 
particle charge although the encapsulation efficiency was insignificantly different (Fig. 3). Therefore, varying pH of 
chitosan, risperidone, and sodium TPP reduced the zeta potential but the encapsulation efficiency was not affected.  
 
 
 
 
 
 
 
 
Fig. 3.Effects of sodium TPP pH 3 and pH 9 on the charge of risperidone nanoparticles. 
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3.9. Modification of surface charge of risperidone 
The main purposes of modifying the surface charge of risperidone was to enhance its interaction with chitosan in 
order enhancing the encapsulation efficiency. Modification was performed by adding SDS (Sodium Dodecyl 
Sulphate) to risperidone solution. It was reported that the opposite charge of chitosan and drug caused a spontaneous 
forming of particles, which were finally improved by adding of sodium TPP4. SDS is an anionic surfactant that has 
highly negatively charge. Addition of SDS into the risperidone solution provided negatively charge to mediate 
interaction with chitosan.  
The use of SDS 0.003% in risperidone solution pH 9 reduced the zeta potential to a negative charge (data not 
shown). Additionally, the higher SDS concentration, the more decrease of surface charge of chitosan-risperidone 
particles. The use of TPP as a hardening agent did not change the pattern of particle charge (Fig. 4). It is likely that 
SDS facilitated the interaction between both positive charge of chitosan and risperidone and it was not affected by 
sodium TPP.  
 
 
 
 
 
 
 
Fig. 4.Effects of SDS on the charge of risperidone nanoparticles. 
Encapsulation efficiency of risperidone with addition of SDS was shown in Fig. 5. Addition of 0.050% SDS 
improved the encapsulation efficiency approximately 25%, while further amount up to 0.250% reached even higher 
the encapsulation efficiency to 100%. 
 
 
 
 
 
 
 
 
Fig. 5.   Effect of SDS on encapsulation risperidone in nanoparticles 
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Effect of addition of SDS on particle size was also investigated. Table 6 showed that the increase of SDS 
concentration from 0.10%-0.25% significantly improved the encapsulation efficiency approximately 100%, but 
followed by increase in particle size up to micron size. This is presumably because high SDS molecules bind to the 
risperidone molecules. Therefore, its interaction with chitosan and sodium TPP leads to larger particles formation.   
Table 6.    Effect of SDS addition on encapsulation efficiency and particle size  
Form.  SDS (%) Encapsulation Efficiency (%) 
Particle Size 
(nm) 
F-69   0.003 0 381.0 
F-70 0.005 4.45 510.4 
F-72 0.010 4.71 365.5 
F-75 0.050 25.62 456.2 
F-73 0.100 57.73 4900.4 
F-74 0.250 100.00 2386.3 
 
4. Conclusion 
Encapsulation of risperidone into chitosan-TPP nanocarrier was increased approximately 25.62% by 
manipulation positively surface charge of risperidone with negatively charge of SDS. Density of crosslinker agent 
SDS plays important role since the use of high density SDS 0.1% tends to enlarge particles to microsize. 
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